73 active trials 29 recruiting 20 Phase 3 18 disease areas 15 changes in 30 days
9 trials changed in the last 30 days: 0 stopped, 6 with notable changes, 3 with minor changes only.
Primary and study completion pushed from May 28, 2031 to Dec 31, 2031
Also in this update: Trial arms changed: 1 → 2
BiogenPhase 3 NCT07444489 Registry history of NCT07444489 on ClinicalTrials.gov (opens the registry)
Updated
Primary and study completion pushed from Mar 29, 2030 to May 3, 2032
BiogenPhase 3 NCT05352919 Registry history of NCT05352919 on ClinicalTrials.gov (opens the registry)
Updated
Primary and study completion pushed from Nov 30, 2026 to Aug 31, 2027
Eisai Co., Ltd.Phase 1 NCT04271488 Registry history of NCT04271488 on ClinicalTrials.gov (opens the registry)
Updated
Recruitment opened
Eisai Inc.Phase 1 NCT07766369 Registry history of NCT07766369 on ClinicalTrials.gov (opens the registry)
Updated
Recruitment opened
Also in this update: Trial sites expanded: 11 → 17 locations
Eisai LimitedNot specified NCT07762092 Registry history of NCT07762092 on ClinicalTrials.gov (opens the registry)
Updated
Primary and study completion moved earlier from Jun 30, 2029 to Dec 31, 2026
Eisai Inc.Phase 3 NCT03887455 Registry history of NCT03887455 on ClinicalTrials.gov (opens the registry)
Updated
Enrollment closed, study ongoing
BiogenPhase 3 NCT06953583 Registry history of NCT06953583 on ClinicalTrials.gov (opens the registry)
Updated
Trial status changed: Not Yet Recruiting → Active, Not Recruiting
Eisai Inc.Not specified NCT07723950 Registry history of NCT07723950 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 261 → 264 locations
BiogenPhase 3 NCT06935357 Registry history of NCT06935357 on ClinicalTrials.gov (opens the registry)
Updated
| First posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-10-08 | NCT07864623 A Postmarketing Study of LEQEMBI in Participants With Alzheimer's Disease | Not Yet Recruiting | |
| 2026-10-02 | NCT07855211 A Study to Learn About the Safety of BIIB147 and Its Effects in Adults With Amyotrophic… | Phase 1/2 | Not Yet Recruiting |
| 2026-09-30 | NCT07849660 Real-World Lenvatinib Sequencing in Unresectable Hepatocellular Carcinoma (uHCC) | Active, Not Recruiting | |
| 2026-09-16 | NCT07821658 A Postmarketing Study of Lecanemab for the Treatment of Participants With Alzheimer's… | Recruiting |
| Phase 1 | 14 | |
| Phase 1/2 | 4 | |
| Phase 2 | 7 | |
| Phase 2/3 | 1 | |
| Phase 3 | 19 | |
| Phase 4 | 2 |
| NCT ID | Title | Condition | Status | Updated |
|---|---|---|---|---|
| Phase 4 | ||||
| NCT07223723 | A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Chinese… | Amyotrophic Lateral Sclerosis | Active, Not Recruiting | 2026-08-13 |
| NCT06964113 | A Study of Filgotinib 200 mg in Korean Participants With Moderately to Severely Active… | Ulcerative Colitis | Active, Not Recruiting | 2026-07-02 |
| Phase 3 | ||||
| NCT07444476 | A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety in… | Spinal Muscular Atrophy | Recruiting | 2026-10-02 |
| NCT06935357 | A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin… | Immunoglobulin A Nephropathy (IgAN) | Recruiting | 2026-09-30 |
| NCT06962800 | A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults… | Primary Membranous Nephropathy | Recruiting | 2026-09-29 |
| NCT07221669 | A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety When… | Muscular Atrophy, Spinal | Recruiting | 2026-08-18 |
| NCT07444450 | A Study to Learn About the Safety and Effects of Salanersen (BIIB115) When Given to… | Muscular Atrophy, Spinal | Recruiting | 2026-08-11 |
| NCT07444489 | A Study to Learn More About the Long-Term Safety and Effects of Felzartamab Infusions in… | Antibody-mediated Rejection | Enrolling by Invitation | 2026-10-09 |
| NCT03887455 | A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early… | Early Alzheimer's Disease | Active, Not Recruiting | 2026-10-06 |
| NCT05352919 | A Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and… | Systemic Lupus Erythematosus (SLE) | Enrolling by Invitation | 2026-10-05 |
| NCT06953583 | A Study to Learn More About the Effects and Long-Term Safety of Omaveloxolone (BIIB141)… | Friedreich Ataxia | Active, Not Recruiting | 2026-10-02 |
| NCT03958877 | A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon… | Multiple Sclerosis, Relapsing-Remitting | Active, Not Recruiting | 2026-09-24 |
| NCT06044337 | A Long-Term Extension Study to Learn More About the Safety of Litifilimab (BIIB059)… | Subacute Cutaneous Lupus Erythematosus | Enrolling by Invitation | 2026-08-04 |
| NCT06685757 | A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults… | Antibody-mediated Rejection | Active, Not Recruiting | 2026-06-05 |
| NCT04468659 | AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in… | Preclinical Alzheimer's Disease | Active, Not Recruiting | 2026-06-04 |
| NCT05067790 | A Study to Learn About the Effect of Higher Doses of Nusinersen (BIIB058) Given as… | Spinal Muscular Atrophy | Active, Not Recruiting | 2026-05-22 |
| NCT04856982 | A Study of BIIB067 (Tofersen) Initiated in Clinically Presymptomatic Adults With a… | Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation | Active, Not Recruiting | 2026-03-30 |
| NCT07483632 | A Study to Learn About the Safety of Diroximel Fumarate (DRF) and Dimethyl Fumarate (DMF)… | Relapsing Forms of Multiple Sclerosis | Not Yet Recruiting | 2026-03-19 |
| NCT02811861 | Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of… | Renal Cell Carcinoma | Active, Not Recruiting | 2026-02-23 |
| NCT04895241 | A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They… | Lupus Erythematosus, Systemic | Active, Not Recruiting | 2026-02-10 |
| NCT04961567 | A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They… | Lupus Erythematosus, Systemic | Active, Not Recruiting | 2026-01-29 |
| Phase 2/3 | ||||
| NCT05531565 | A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of… | Subacute Cutaneous Lupus Erythematosus | Active, Not Recruiting | 2026-10-09 |
| Phase 2 | ||||
| NCT07722546 | A Study to Learn About The Effects of Felzartamab on Thyroid Function and Its Safety in… | Graves' Disease | Recruiting | 2026-10-07 |
| NCT07219043 | A Study to Learn About the Effects of Felzartamab Infusions in Adults With Kidney… | Microvascular Inflammation | Recruiting | 2026-10-06 |
| NCT07515014 | A Study of E6742 in Participants With Systemic Lupus Erythematosus | Systemic Lupus Erythematosus | Recruiting | 2026-08-21 |
Alzheimer's Disease (13) · Spinal Muscular Atrophy (10) · Lupus (SLE) (6) · Multiple Sclerosis (6) · ALS (4) · Colorectal Cancer (2) · Epilepsy (2) · Liver Cancer (2) · Ulcerative Colitis (2) · Breast Cancer (1)